4.6 Review

Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?

Journal

FRONTIERS IN MEDICINE
Volume 8, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2021.686778

Keywords

inflammatory bowel disease; iron deficiency anemia; iron supplementation; anemia; parenteral iron supplementation; oral iron supplementation

Funding

  1. National Research, Development and Innovation Office [125377, 129266, 134863]
  2. National Excellence Programme [20391-3/2018/FEKUSTRAT]
  3. New National Excellence Program of the Ministry of Human Capacities [UNKP-19-4-SZTE-44, UNKP-20-5-SZTE-161]
  4. Janos Bolyai Research Grant [BO/00598/19/5]
  5. Faculty of Medicine, University of Szeged

Ask authors/readers for more resources

Iron deficiency anemia is a common extraintestinal manifestation of inflammatory bowel disease, significantly impacting patients' quality of life and mortality rate. Effective treatment requires addressing underlying pathological changes, and both oral and intravenous iron should be used more frequently.
One of the most common extraintestinal manifestations of inflammatory bowel disease is iron deficiency anemia. It is often an untreated condition that significantly impairs patients' quality of life and elevates mortality and morbidity. Although it is often accompanied by mild symptoms (e.g., fatigue, lethargy), it can provoke severe health conditions, such as dyspnea, palpitation, angina, and mental disorders, and increases hospitalization and mortality rate as well. As anemia develops through several pathomechanisms, such as occult bleeding, chronic inflammation, and medicines (e.g., methotrexate), treating anemia effectively requires to manage the underlying pathological changes as well. Based on international publications and data, it is a frequent condition and more frequent in pediatrics. According to Goodhand et al., iron deficiency is present in more than 60% of children, whereas only 14% of them received oral iron therapy. Compared to adult patients, 22% have iron deficiency, and 48% of them received oral and 41% intravenous iron therapy. Miller et al. also highlighted that among young patients iron deficiency anemia is a frequent condition, as almost 50% of the patients were anemic in their cohort. European Crohn's and Colitis Organisation's statements are clear regarding the diagnosis of iron deficiency anemia, and the iron supplementation as well. Third-generation parenteral iron supplementations seem to be safer and more effective than oral iron pills. Oral iron in many cases cannot replace the iron homeostasis as well; furthermore, it can provoke dysbiosis, which can potentially lead to relapse. As a result, we claim that both oral and parenteral should be used more frequently; furthermore, intravenous iron could replace oral medicines as well in certain cases. Despite the fact that iron deficiency anemia is examined by many aspects, further questions can be raised. Can it imply underlying pathological lesions? Are both oral and intravenous iron therapy safe and effective? When and how are they used? We demand that more studies should be conducted regarding these issues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available